By Mayo Clinic Staff
The quad screen — also known as the quadruple marker test, the second trimester screen or simply the quad test — is a prenatal test that measures levels of four substances in a pregnant woman's blood:
- Alpha-fetoprotein (AFP), a protein made by the developing baby
- Human chorionic gonadotropin (HCG), a hormone made by the placenta
- Estriol, a hormone made by the placenta and the baby's liver
- Inhibin A, another hormone made by the placenta
Ideally, the quad screen is done between weeks 15 and 18 of pregnancy — the second trimester. However, the procedure can be done up to week 20.
The quad screen is used to evaluate whether your pregnancy has an increased chance of being affected with certain chromosomal conditions, such as Down syndrome. The alpha-fetoprotein part of the test can help evaluate the chance for neural tube defects, such as spina bifida, and abdominal wall defects, such as omphalocele.
If your risk level is low, the quad screen can offer reassurance that there is a decreased chance for Down syndrome, trisomy 18, neural tube defects and abdominal wall defects. If the quad screen indicates an increased chance of one of these conditions, you might consider additional screening or testing.
The quad screen is done to evaluate your chance of carrying a baby who has any of the following conditions:
- Down syndrome (trisomy 21). Down syndrome is a chromosomal disorder that causes lifelong intellectual disability and developmental delays and, in some people, health problems.
- Trisomy 18. This is a chromosomal disorder that causes severe developmental delays and anatomic abnormalities. Trisomy 18 is often fatal by age 1.
- Spina bifida. Spina bifida is a serious birth defect that occurs when a portion of the neural tube fails to develop or close properly, causing defects in the spinal cord and in the bones of the spine.
- Anencephaly. Anencephaly is a serious birth defect in the closure of the neural tube, resulting in an underdeveloped brain and an incomplete skull.
The quad screen has traditionally been the most commonly used screening in the second trimester. It was generally used if prenatal care began during the second trimester or if first trimester screening, which involves a blood test and an ultrasound exam, wasn't available. Your health care provider might combine the results of first trimester screening with the quad screen to improve the detection rate of Down syndrome.
Prenatal cell-free DNA screening is a new screening method that your health provider might recommend in place of quad screening. Talk to your health care provider about your screening options.
Remember, the quad screen is not a diagnostic test. Test results only indicate whether you have an increased chance of carrying a baby with certain chromosomal abnormalities, such as Down syndrome, or neural tube defects, such as spina bifida. A negative quad screen doesn't guarantee that the baby won't have a chromosomal abnormality, single gene disorder or certain birth defects. If your screening test is positive, your doctor will recommend additional testing to make a diagnosis.
Before the screening, think about what the results mean to you. Consider whether the screening will be worth any anxiety it might cause, or whether you'll handle your pregnancy differently depending on the results. You might also consider what level of risk would be enough for you to choose a more invasive follow-up test.
The quad screen is a routine prenatal screening test. The test poses no risk of miscarriage or other pregnancy complications.
As with other prenatal screening tests, however, the quad screen can cause anxiety about the possible test results and what they might mean for your baby.
Prior to your test, your health care provider might ask you to meet with a genetic counselor to discuss the test. Alternatively, your health care provider might provide genetic counseling during your routine prenatal care appointment.
You can eat and drink normally before the test.
During the quad screen, a member of your health care team takes a sample of blood by inserting a needle into a vein in your arm. The blood sample is sent to a lab for analysis. You can return to your usual activities immediately.
The quad screen measures levels of AFP, HCG, estriol and inhibin A in a pregnant woman's blood. Your health care provider will use your age at the estimated time of delivery and the results of the quad screen to evaluate your chance of carrying a baby who has certain chromosomal conditions, neural tube defects or abdominal wall defects.
Quad screen results are given as a probability, such as a 1 in 500 risk of carrying a baby who has Down syndrome. Keep in mind that a positive quad screen simply means that levels of some or all of the substances measured in your blood were outside the normal range. Factors that can affect the substances measured by a quad screen include:
- A miscalculation of your baby's age (how long you've been pregnant)
- Maternal race
- Maternal weight
- A multiple pregnancy
- In vitro fertilization
- Smoking during pregnancy
If your test results are positive, your health care provider might recommend an ultrasound to verify the baby's gestational age and confirm the number of babies.
The quad screen correctly identifies about 80 percent of women who are carrying a baby who has Down syndrome. About 5 percent of women have a false-positive result, meaning that the test result is positive but the baby doesn't actually have Down syndrome.
When you consider your test results, remember that the quad screen only indicates your overall chance of carrying a baby who has certain chromosomal conditions or neural tube defects. A decreased chance (negative screen result) doesn't guarantee that your baby won't have one of these conditions. Likewise, an increased chance (positive screen result) doesn't guarantee that your baby will be born with one of these conditions.
Often, positive screen results are an invitation to consider secondary testing. For example:
- Prenatal cell-free DNA screening. This sophisticated blood test examines cell-free DNA from the placenta and the fetus in the maternal bloodstream. This screening evaluates whether your baby is at risk of Down syndrome, extra sequences of chromosome 13 (trisomy 13), extra sequences of chromosome 18 (trisomy 18) or a sex chromosome abnormality, such as Turner syndrome. A normal result might eliminate the need for an invasive prenatal diagnostic test.
- Targeted ultrasound. If you're at high risk of a neural tube defect, your health care provider might suggest a targeted ultrasound. Ultrasound isn't an effective screening tool for Down syndrome.
- Chorionic villus sampling (CVS). This procedure can be used to diagnose chromosomal conditions, such as Down syndrome. During CVS, which is usually done during the first trimester, a sample of tissue from the placenta is removed for testing. CVS poses a slight risk of miscarriage and isn't useful in detecting neural tube defects, such as spina bifida.
- Amniocentesis. Amniocentesis can be used to diagnose both chromosomal conditions, such as Down syndrome, and neural tube defects, such as spina bifida. During amniocentesis, which is usually done during the second trimester, a sample of amniotic fluid is removed from the uterus for testing. Like CVS, amniocentesis poses a slight risk of miscarriage.
Your health care provider or a genetic counselor will help you understand your test results and what the results mean for your pregnancy.
Oct. 21, 2015
- Messerlian GM, et al. Down syndrome: Overview of prenatal screening. http://www.uptodate.com/home. Accessed Aug. 6, 2015.
- Messerlian GM, et al. Laboratory issues related to maternal serum screening for Down syndrome. http://www.uptodate.com/home. Accessed Aug. 6, 2015.
- Messerlian GM, et al. First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18. http://www.uptodate.com/home. Accessed Aug. 6, 2015.
- NINDS anencephaly information page. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/anencephaly/anencephaly.htm. Accessed Aug. 6, 2015.
- NINDS spina bifida information page. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/spina_bifida/spina_bifida.htm. Accessed Aug. 6, 2015.
- Ostermaier KK. Down syndrome management. http://www.uptodate.com/home. Accessed Aug. 6, 2015.
- Frequently asked questions. Pregnancy. Screening tests for birth defects FAQ165. American College of Obstetricians and Gynecologists. http://www.acog.org/Patients/FAQs/Screening-Tests-for-Birth-Defects. Accessed Aug. 6, 2015.
- Bianchi DW, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstetrics & Gynecology. 2012;119:890.
- Cunningham FG, et al. Prenatal diagnosis. In: Williams Obstetrics. 24th ed. New York, N.Y.: The McGraw-Hill Companies; 2014. http://www.accessmedicine.com. Accessed Aug. 3, 2015.
- Fischbach FT, et al. Prenatal diagnosis and tests of fetal well-being. In: A Manual of Laboratory and Diagnostic Tests. 9th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2014.
- Beckmann CRB, et al. Genetics and genetic disorders in obstetrics and gynecology. In: Obstetrics and Gynecology. 7th ed. Baltimore, Md.: Lippincott Williams & Wilkins; 2014.
- Hochberg L, et al. Prenatal screening and diagnosis of neural tube defects. http://www.uptodate.com/home. Accessed Aug. 6, 2015.
- Wolfberg A, et al. Noninvasive prenatal testing using cell-free nucleic acids in maternal blood. http://www.uptodate.com/home. Accessed Aug. 7, 2015.
- AskMayoExpert. Prenatal screening: Types of screening tests. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.